ERAS · Erasca, Inc.
$19.34
-2.59% last session
End-of-day data · updated 2026-07-25
Market cap
$7B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
-34.6
Dividend yield
—
Beta
0.66
Avg volume
7M
Employees
0K
2D change
-1.19%
5D change
1.54%
10D change
-10.11%
30D change
27.83%
60D change
66.17%
MTD change
6.64%
YTD change
413.71%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ERAS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$21.00
+8.6% vs priceBank of America
Neutral$18.00
-6.9% vs priceJP Morgan
Overweight$25.00
+29.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Morgan Stanley | Maintains | Equal-Weight | $12.00 → $21.00 |
| 2026-07-14 | Bank of America | Maintains | Neutral | $16.00 → $18.00 |
| 2026-06-04 | Bank of America | Upgrade | Underperform → Neutral | $9.00 → $16.00 |
| 2026-05-12 | Mizuho | Maintains | Outperform | $28.00 → $26.00 |
| 2026-04-27 | Stifel | Maintains | Buy | $20.00 → $30.00 |
| 2026-03-18 | JP Morgan | Maintains | Overweight | $24.00 → $25.00 |
| 2026-03-16 | Guggenheim | Maintains | Buy | $12.00 → $20.00 |
| 2026-03-13 | Piper Sandler | Maintains | Overweight | $11.00 → $18.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 24.1% above the 50-day MA ($15.18).
- Price vs 200-day MA: Trading 79.3% above the 200-day MA ($10.51).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.18) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($1.39) and high ($22.47).
ERAS Price Chart
Loading chart for ERAS…
Fundamentals
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.